Replies to post #362793 on Amarin Corp Plc (AMRN)

[couldbebetter]

Not too bad! Raf, As always, appreciate ALL your efforts here!

[Number sleven]

Raf, Thanks.
Sleven,

[rosemountbomber]

Thanks Raf.

[Megc]

Thanks Raf! I really appreciate your work every week.

[Nukemtiltheyglow]

Raf; thanks for the Scripts update. One of these days these numbers will do a reversal....

Nuke

[rafunrafun]

Scripts for week ending December 10, 2021

Overall drug TRx: +0.3% w/w

Vascepa
TRx 83,075; +1.3% (+1,091) w/w; -5.7% y/y
NRx 37,688; +4.9% (+1,763) w/w; -4.6% y/y
Ref 45,387; -1.5% (-672) w/w; -6.5% y/y

Lovaza (Generic & Brand)
TRx 65,758; +0.7% (+475) w/w; +0.5% y/y
NRx 32,730; +0.8% (+268) w/w; -0.4% y/y
Ref 33,029; +0.6% (+207) w/w; +1.4% y/y

Generic Vascepa
TRx 23,900; +2.1% (+489) w/w; As % of total V: 22.3%
NRx 13,400; +4.5% (+571) w/w; As % of total V: 26.2%
Ref 10,500; -0.8% (-82) w/w; As % of total V: 18.8%

Generic Vascepa by Manufacturer
Hikma - TRx 13,470 (-134); Generic share 55.8%; Total V share 12.5%
Hikma - TRx 10,565 (+624); Generic share 44.2%; Total V share 9.9%

Vascepa + Generic Vascepa
TRx 106,975; +1.5% (+1,581) w/w
NRx 51,088; +4.8% (+2,334) w/w
Ref 55,887; -1.3% (-754) w/w